Gilead Laboratories, has made a call for the purpose of promoting research in patients with Hepatitis B virus.

This program will allocate funds in order to include in treatment programs those patients affected by hepatitis B, who for one reason or another are not receiving treatment, as well as to verify which causes may be influencing the low proportion of treatment to patients who thus require it.

We believe that this is an opportunity for interested members to submit a proposal that benefits this population of HBV patients.